Artak Labadzhyan, MD
Endocrinology, Diabetes & Metabolism · West Hollywood, CANPI 1841516184
Payments from drug & device makers
Across 19 payments — averaging $2265.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiasma, Inc.$17K
- Ascendis Pharma Endocrinology Inc$16K
- Amryt Pharma Holdings Ltd$9K
- Pfizer$117
Across 1 payment — averaging $650.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amryt Pharma Holdings Ltd$650
What the payments were for
- Consulting fees$6,00085%
- Travel & lodging$6029%
- Food & beverage$4356%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiasma, Inc. | 8 | $17,428 |
| Ascendis Pharma Endocrinology Inc | 3 | $16,087 |
| Amryt Pharma Holdings Ltd | 7 | $9,409 |
| Pfizer | 1 | $117 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYCAPSSA$6,919
How this compares
$43,041 in reported general payments places this provider in the 85th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 129 | $163,521 |
| JardianceEmpagliflozin | 62 | $75,041 |
| Teriparatide | 29 | $68,599 |
| MounjaroTirzepatide | 34 | $50,596 |
| TrulicityDulaglutide | 12 | $23,050 |
| TradjentaLinagliptin | 19 | $20,651 |
| Testosterone | 53 | $16,131 |
| SynthroidLevothyroxine Sodium | 118 | $10,625 |
| Hydrocortisone | 73 | $3,751 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 35 | $2,759 |
| Levothyroxine Sodium | 231 | $2,205 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $1,572 |
| Nateglinide | 15 | $1,076 |
| Alendronate Sodium | 23 | $909 |
| Armour ThyroidThyroid,pork | 25 | $654 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in West Hollywood
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Stanley HsiaLos Angeles$19.8M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
- Athena Philis-Tsimikasla Jolla$6M
- David AhnNewport Beach$5.8M
- Shlomo MelmedLos Angeles$3.3M
- Leila ChaychiSan Carlos$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.